Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
Heather J. Symons(Johns Hopkins University), Ephraim J. Fuchs(Johns Hopkins Hospital), B. Douglas Smith(Johns Hopkins University), Leo Luznik(Sidney Kimmel Comprehensive Cancer Center), Yilin Cao(Sidney Kimmel Comprehensive Cancer Center), Ivan Borrello(Johns Hopkins University), Amy E. DeZern(Johns Hopkins University), Richard J. Jones(Sidney Kimmel Cancer Center), Christopher Gamper(Johns Hopkins University), Kenneth R. Cooke(Sidney Kimmel Comprehensive Cancer Center), Orly R. Klein(Sidney Kimmel Comprehensive Cancer Center), Nicolás J. Llosa(Sidney Kimmel Comprehensive Cancer Center), Ivana Gojo(Johns Hopkins University), Marianna Zahurak(Bloomberg (United States)), Richard F. Ambinder(Johns Hopkins University), Robert A. Brodsky(Johns Hopkins University), Allen Chen(Johns Hopkins University), Margaret M. Showel(Johns Hopkins University), Elias T. Zambidis(University of Maryland, Baltimore), Lode J. Swinnen(Johns Hopkins University), Javier Bolaños‐Meade(Johns Hopkins University)
Cited by 73
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
|Cancer Discovery|2014|1.5k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k